Key takeaways
Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) and Advair (fluticasone/salmeterol) are both inhaled medications used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). They both contain an inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA), but Breztri also includes a long-acting muscarinic antagonist (LAMA), making it an ICS/LAMA/LABA combination, while Advair is an ICS/LABA combination. Breztri is specifically approved for COPD, whereas Advair is approved for both COPD and asthma, with Advair Diskus being the form used for COPD. Breztri is taken as two inhalations twice daily, while Advair Diskus is typically one inhalation twice daily for COPD. Breztri is only available as a brand-name medication, whereas Advair has a generic version called Wixela Inhub. Common side effects of Breztri include upper respiratory tract infections and pneumonia, while Advair can cause upper respiratory infections, sore throat, and headaches. Both medications can increase the risk of fungal infections in the mouth, so it's important to rinse your mouth after use. Additionally, Breztri should not be used with other LABA-containing inhalers.
